Scipher Medicine, a Waltham, Mass.-based precision immunology company matching patients with the most effective therapy, completed an $82m Series C financing.
The round was led by aMoon and Northpond Ventures, with participation from Echo Health Ventures and existing investors, Khosla Ventures and Alumni Ventures.
The company, which has raised $117m in total funding to date, intends to use the funds to expand commercial efforts for its patient molecular signature test, PrismRA.
Led by Alif Saleh, Chief Executive Officer, Scipher is a precision immunology company that leverages a proprietary Network Medicine platform and artificial intelligence to commercialize blood tests revealing a persons’ unique molecular disease signature and match such signature to the most effective therapy. The company partners with payers, providers, and pharma along the health care value chain to bring precision medicine to autoimmune diseases.
PrismRA, the company’s molecular signature test, brings precision medicine to the treatment of rheumatoid arthritis. From a routine blood draw, the PrismRA test analyzes an individual’s molecular signature, helping identify who is unlikely to adequately respond to TNFi therapy, so non-responders can be prescribed alternative effective therapy.